A 72-year-old male presented with urinary symptoms. His serum prostate specific antigen level was 65.2 ng/ml. His radical prostatectomy specimen showed clear cell lesion reminiscent of the clear cell renal cell carcinoma along with acinar type of prostatic adenocarcinoma, Gleason score 4 + 4. The lesional clear cells were positive for pancytokeratin, epithelial membrane antigen, CD10, vimentin, and AMACR while negative for 34βE12, CK7, prostate specific antigen, and PAX8. The final diagnosis was renal-type clear cell carcinoma of the prostate. A follow-up of 20 months did not show metastasis. We herein report fifth case of renal-type clear cell carcinoma of the prostate.

No abstract

Background: In India, the uterine broid is a common indication of hysterectomy. An effective option for medical treatment may decrease the morbidity associated with hysterectomy. Objectives: We aimed to evaluate the effect of mifepristone (25 mg), progesterone antagonist, on uterine broids in perimenopausal women. Material And Methods: Fifty perimenopausal women having symptomatic uterine broids were selected from Gynaecology OPD and given 25 mg mifepristone once daily continuously for 2–4 cycles of 3 months each. Variables such as baseline broid size, position, and haemoglobin were measured and followed at 3, 6, 9, and 12 months. The data were entered in MS EXCELspreadsheet and analysis was done using Statistical Package for Social Sciences (SPSS) version 21.0. APvalue of <0.05 was considered as statistically signicant. Results: Majority were intramural broids (70%) followed by submucosal in 18%. Size of broids ranged from 7 cm; the majority of broids were in 5–7 cm size. No signicant association of location with the size of broid was found. Out of 50 cases included in the study, change in size in uterine broids was observed in 95.14% cases. There was an increase in haemoglobin, from 8.6 g% at baseline to 9.5 g% at 12 months. Conclusion: Mifepristone resulted in a reduction in uterine broids size and an increase in haemoglobin at the end of 12 months. It may be an option for uterine leiomyoma treatment, as it is given orally, cost-effective and has minimal side effects.